Where cancer research, innovation and treatment come together.
A world-leading District
In partnership with The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Aviva Capital Markets, Socius and Sutton Borough Council, the London Cancer District brings together world-class science, specialist healthcare and the local community.
New research and innovation space will sit alongside a wealth of amenities, generous green spaces and improved transport links, creating a welcoming place for everyone who works in, lives near or visits London Cancer District.
A place designed for discovery, and for everyday life.
The London Cancer District brings world-leading science and healthcare together with welcoming public spaces, everyday amenities and nature.
At its heart, a network of green spaces, plazas and pedestrian routes brings people together, with places to meet, share ideas, take a break or simply enjoy being outdoors. Lively gathering spaces sit alongside quieter, biodiversity-rich areas that make the most of the District’s existing natural assets.
Designed for everyone who works in, lives near or visits the District, the public spaces support collaboration, community, health and wellbeing.
Facts & figures
3,000
jobs on site at the District, 1,200 of these for local people
£1.2bn
contribution to UK economy, £11.9m annual local spend by 2035
340
construction jobs, plus 142 apprenticeship positions
£5.5m
in additional business rates annually, 50% retained by the Borough
People & stories
Kristian Helin, CEO of The Institute of Cancer Research gives an overview of our new five-year strategy.
At The Institute of Cancer Research, London, we work with our clinical partner The Royal Marsden NHS Foundation Trust, and organisations across the UK and internationally, to transform the lives of cancer patients and their families.
Vesynta – Patient Personalised Dosing
Listen to Dr Alaric Taylor talking about Vesynta at The London Cancer District. Vesynta’s DosoLogic is the prescribing co-pilot that brings model-informed precision dosing (MIPD) to the point of care for safer, patient-specific doses.
Planning permission granted
Plans for the £1 billion expansion of London Cancer Hub, led by Aviva Capital Partners and development manager Socius, have been approved by Sutton Council. Granted on World Cancer Day (4 February), the scheme will deliver around 1 million sq ft of laboratory and research space across 12 acres, supporting collaboration between researchers, clinicians, start-ups and global life sciences companies.
ExoNostic – Next-generation liquid biopsy diagnostics
Listen to Dr Meysam Keshavaraz talking about ExoNostic at The London Cancer District. ExoNostic is developing next-generation liquid biopsy diagnostics that enable earlier and more accessible disease detection. Their platform applies holistic molecular analysis to small biological samples, generating detailed diagnostic insights that support early cancer detection, treatment monitoring and wider biomarker discovery.
Kindling Bio – Pioneering child-first gene therapy platform
Listen to Jeff Drew talking about Kindling Bio at The London Cancer District. Kindling Bio is a London-based biotechnology start-up treating one scalable gene therapy to flag multiple childhood tumors for immune destruction.
Our partners
